CAS 329045-45-6
:ReMogliflozin A
Description:
ReMogliflozin A is a chemical compound classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. It functions by inhibiting the reabsorption of glucose in the kidneys, thereby promoting glucose excretion in urine and helping to lower blood glucose levels. The compound is characterized by its selective action on the SGLT2 transporter, which is crucial for glucose reabsorption in the renal proximal tubules. ReMogliflozin A is known for its potential to improve glycemic control, reduce body weight, and lower blood pressure in diabetic patients. Additionally, it may have beneficial effects on cardiovascular health. The chemical structure of ReMogliflozin A includes specific functional groups that contribute to its pharmacological activity and solubility properties. As with other SGLT2 inhibitors, it is essential to monitor for potential side effects, including urinary tract infections and dehydration. Overall, ReMogliflozin A represents a significant advancement in diabetes treatment options.
Formula:C23H34N2O7
Synonyms:- Remogliflozin - GSK 189074
- ReMogliflozin A
- ReMogliflozin
- (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxane-3,4,5-triol
- β-D-Glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl
- GSK 189074
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Remogliflozin
CAS:<p>Inhibitor of sodium-glucose cotransporter SGLT2</p>Formula:C23H34N2O7Purity:Min. 95%Molecular weight:450.53 g/molRemogliflozin
CAS:<p>Remogliflozin is an effective sodium-glucose transporter 2 inhibitor (Kis = 12.4 and 26 nM for human and rat SGLT2, respectively).</p>Formula:C23H34N2O7Color and Shape:SolidMolecular weight:450.53
